. 2024 Dec 5;14:30341. doi: 10.1038/s41598-024-82106-2

Table 4.

Comparison of clinicopathological characteristics of patients according to FOXP3 status by Chi-square test.

	Low FOXP3+ (n = 99)	High FOXP3+ (n = 108)	p-value
Age, mean (SD)^*	54.8 (13.3)	53.6 (11.6)	0.8
Body mass index (kg/m²), mean (SD)	30.3 (5.7)	31.2 (6.3)	0.48
Menopause status n (%) Premenopausal Postmenopausal	43 (43.4) 56 (56.6)	42 (38.9) 66 (61.1)	0.50
Histological subtype, n (%) Invasive ductal carcinoma Invasive lobular carcinoma Mix^¶ Others ^†	80 (80.8) 10 (10.1) 2 (2.0) 7 (7.1)	98 (90.7) 3 (2.8) 1 (0.9) 6 (5.6)	0.11
ER, n (%) Negative Positive	9 (9.1) 90 (90.7)	18 (16.7) 90 (83.3)	0.15
ER percentage, mean (SD)	75.0 (29.2)	64.5 (35.2)	0.03
PR, n (%) Negative Positive	12 (12.1) 87 (87.9)	30 (27.8) 78 (72.2)	0.009
PR percentage, mean (SD)	60.5 (35.9)	45.2 (36.6)	0.001
HER2, n (%) Negative Positive	88 (88.9) 11 (11.1)	87 (80.6) 21 (19.6)	0.14
Triple-negative, n (%) Absent Present	95 (96.0) 4 (4.0)	97 (89.8) 11 (10.2)	0.15
Molecular subtype, n (%) HR + HER2- HR + HER2+ HR- HER2+ HR- HER2- (triple-negative)	84 (84.8) 7 (7.1) 4 (4.0) 4 (4.0)	76 (70.4) 15 (13.9) 6 (5.6) 11 (10.2)	0.09
Molecular subtype, n (%) Luminal A Luminal B (HER2-) Luminal B (HER2+) HR- HER2+ HR- HER2- (triple-negative)	35 (35.4) 49 (49.5) 7 (7.1) 4 (4.0) 4 (4.0)	33 (30.6) 43 (39.8) 15 (13.9) 6 (5.6) 11 (10.2)	0.16
Nuclear grade n (%) Grade1 Grade2 Grade3	33 (34.4) 48 (50.0) 15 (15.6)	22 (21.2) 49 (47.1) 33 (31.7)	0.014 0.02 0.34 0.003^**
Ki67, n (%) <%20 ≥%20	51 (53.7) 44 (46.3)	37 (35.9) 66 (64.1)	0.012
Ki67 (%), mean (SD)	22.3 (17.6)	31.6 (25.1)	0.029
Lymphovascular invasion, n (%) Absent Present	45 (50.0) 45 (50.0)	48 (50.0) 48 (50.0)	1.0
Perineural invasion, n (%) Absent Present	42 (61.8) 26 (38.2)	44 (62.9) 26 (37.1)	0.89
Pathological T stage, n (%) T1-T2 T3-T4	85 (88.5) 11 (11.5)	97 (91.5) 9 (8.5)	0.63
Pathological N stage, n (%) N0 N1 N2 N3	47 (50.5) 28 (30.1) 12 (12.9) 6 (6.5)	63 (60.0) 20 (19.0) 12 (11.4) 10 (9.5)	0.26
TNM stage, n (%) Stage 1 Stage 2 Stage 3 Stage 4	23 (23.2) 44 (44.4) 21 (21.2) 11 (11.1)	18 (16.7) 60 (55.6) 20 (18.5) 10 (9.3)	0.42
Relapse, n (%) Absent Present	73 (93.6) 5 (6.4)	79 (89.8) 9 (10.2)	0.54

Low FOXP3+ (n = 99)

High FOXP3+ (n = 108)

p-value

Age, mean (SD)^*

54.8 (13.3)

53.6 (11.6)

0.8

Body mass index (kg/m²), mean (SD)

30.3 (5.7)

31.2 (6.3)

0.48

Menopause status n (%)

Premenopausal

Postmenopausal

43 (43.4)

56 (56.6)

42 (38.9)

66 (61.1)

0.50

Histological subtype, n (%)

Invasive ductal carcinoma

Invasive lobular carcinoma

Mix^¶

Others ^†

80 (80.8)

10 (10.1)

2 (2.0)

7 (7.1)

98 (90.7)

3 (2.8)

1 (0.9)

6 (5.6)

0.11

ER, n (%)

Negative

Positive

9 (9.1)

90 (90.7)

18 (16.7)

90 (83.3)

0.15

ER percentage, mean (SD)

75.0 (29.2)

64.5 (35.2)

0.03

PR, n (%)

Negative

Positive

12 (12.1)

87 (87.9)

30 (27.8)

78 (72.2)

0.009

PR percentage, mean (SD)

60.5 (35.9)

45.2 (36.6)

0.001

HER2, n (%)

Negative

Positive

88 (88.9)

11 (11.1)

87 (80.6)

21 (19.6)

0.14

Triple-negative, n (%)

Absent

Present

95 (96.0)

4 (4.0)

97 (89.8)

11 (10.2)

0.15

Molecular subtype, n (%)

HR + HER2-

HR + HER2+

HR- HER2+

HR- HER2- (triple-negative)

84 (84.8)

7 (7.1)

4 (4.0)

76 (70.4)

15 (13.9)

6 (5.6)

11 (10.2)

0.09

Molecular subtype, n (%)

Luminal A

Luminal B (HER2-)

Luminal B (HER2+)

HR- HER2+

HR- HER2- (triple-negative)

35 (35.4)

49 (49.5)

7 (7.1)

4 (4.0)

33 (30.6)

43 (39.8)

15 (13.9)

6 (5.6)

11 (10.2)

0.16

Nuclear grade n (%)

Grade1

Grade2

Grade3

33 (34.4)

48 (50.0)

15 (15.6)

22 (21.2)

49 (47.1)

33 (31.7)

0.014

0.02

0.34

0.003^**

Ki67, n (%)

<%20

≥%20

51 (53.7)

44 (46.3)

37 (35.9)

66 (64.1)

0.012

Ki67 (%), mean (SD)

22.3 (17.6)

31.6 (25.1)

0.029

Lymphovascular invasion, n (%)

Absent

Present

45 (50.0)

48 (50.0)

1.0

Perineural invasion, n (%)

Absent

Present

42 (61.8)

26 (38.2)

44 (62.9)

26 (37.1)

0.89

Pathological T stage, n (%)

T1-T2

T3-T4

85 (88.5)

11 (11.5)

97 (91.5)

9 (8.5)

0.63

Pathological N stage, n (%)

47 (50.5)

28 (30.1)

12 (12.9)

6 (6.5)

63 (60.0)

20 (19.0)

12 (11.4)

10 (9.5)

0.26

TNM stage, n (%)

Stage 1

Stage 2

Stage 3

Stage 4

23 (23.2)

44 (44.4)

21 (21.2)

11 (11.1)

18 (16.7)

60 (55.6)

20 (18.5)

10 (9.3)

0.42

Relapse, n (%)

Absent

Present

73 (93.6)

5 (6.4)

79 (89.8)

9 (10.2)

0.54

^*SD; standard deviation, ^** The adjusted new p-value is 0.008, ¶ Mix; Tumors that have at least two different histological types, †Others; subtypes include medullary carcinoma, mucinous carcinoma, metaplastic carcinoma, papillary carcinoma, and tubular carcinoma.